Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Isis Pharmaceuticals Inc ISIS

Sector: Healthcare | Sub-Sector: Biotechnology

Isis Pharmaceuticals Inc is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs.
Price: $62.46 Volume: 325,589
Change: +$0.03 % Change: +0.05%
Day High/Low: 62.94/61.65 52 Week High/Low: 77.80/37.38
Last Traded: November 27, 2015 08:00 Transaction Volume: 159
Open: 62.30 Previous Close: 62.43
Bid: Ask:
Bid Size: 0 Ask Size: 0
Market Cap: 7.5b Shares Out: 120.1m
PE Ratio: 520.5 Dividend Yield: N/A

Latest Bullboard Posts

  • VP exercised options

    0 stars

    A vice president of Isis Pharmaceuticals Inc. exercised options for 12,200 shares of common stock and sold them under a prearranged...

    1 star

  • news and potential uptrend

    0 stars

     Isis Pharmaceuticals last week reported a sharp drop in its net loss for 2007 despite higher operating expenses as the company...

    1 star

  • Overview of the stock

    0 stars

    Here are some points to consider:1) Biotech industry is very volatile though ISIS stock prices started accelerating upwards in August and...

    0 stars

  • isis needs a kiss of life

    0 stars

    Maybe Tobin is the on the 27th April,07 @ $10.22

    2.5 stars

  • Tobin Smith is pumping ISIS presently

    0 stars

    Wow, I can't believe that no one has left a message on this board since 2003. Toby Smith (Tobin) is calling this one a major buy-out...

    0 stars